cytochrome c oxidase assembly factor 1Genealiases: C7orf44 · MITRAC15
Q-omics provides the consensus-scored COA1 profile across patient tissues and cancer cell-line models. COA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COA1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, COA1 RNA expression shows 20,653 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where COA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COA1 survival associations across molecular data types. COA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COA1 RNA expression–survival associations across cancer types. High COA1 expression shows unfavorable associations in UVM, LIHC, LGG, ACC, HNSC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COA1 RNA expression.
This table summarizes COA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for COA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COA1 shows higher tumor expression in BLCA, COAD, LUAD, LIHC, STAD and KIRP. The BLCA box plot shows higher COA1 RNA expression in tumor versus normal tissue (log2 FC = +0.807, t-test p < 0.001).
This table shows molecular features associated with COA1 in patient tissues and cancer cell lines. In patient samples, COA1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
